A 3-month daily dose of fish hydrolysate — containing 1 g of low-molecular-weight peptides and just 30 mg of long-chain omega-3 PUFAs — significantly improved episodic memory in 53 healthy older adults (ages 60–73) identified as "decliners": those with above-average age-related cognitive decline but no subjective complaints. The Paired Associates Learning Total Error Adjusted score improved with β = −11.75 (P = 0.003), spatial working memory strategy improved (P = 0.018), erythrocyte omega-3 levels rose measurably, and serum CRP dropped significantly — suggesting a genuine anti-inflammatory mechanism rather than placebo effect.
What makes this finding notable is the low omega-3 dose: 30 mg daily is far below the 1–2 g typically used in omega-3 cognition trials, implying the marine peptide fraction — not the fatty acid load alone — may be driving the benefit. This aligns with emerging research showing bioactive fish-derived peptides can modulate neuroinflammation and synaptic plasticity independently of PUFA content. The trial is rigorous for its size: double-blind, randomized, placebo-controlled with validated neuropsychological battery assessments. However, the cohort is small (n=53), the intervention period short (3 months), and the population highly specific — cognitively normal decliners without subjective complaints, a group rarely targeted in trials. Whether effects persist, generalize to broader populations, or translate to dementia risk reduction remains untested. Still, for a food-derived intervention, this is an unusually clean signal: incremental in scope but potentially paradigm-shifting for nutritional cognitive aging strategies.
